Latest disclosed round
Series D
- Date
- 2024-03-01
- Amount
- GBP 25.2m
- Sector
- Biotech & techbio
- Companies House
- 07630933
Later stage / growth
Mission Therapeutics
Deubiquitylating enzyme (DUB) inhibitor drug discovery
CandidateSeries DCambridge
Evidence status
Review retained
- Identity
- Candidate
- Match
- High candidate
- Operating status
- active
- Data origins
- Core directory, Growth Network, Live Chris T D1
Capital network
6 linked investors
Funding record
1 disclosed round
| Date | Stage | Amount | Investors |
|---|---|---|---|
| 2024-03-01 | Series D | £25.2M | Pfizer Venture Investments, Sofinnova Partners, Roche Venture Fund, SR One, IP Group, Rosetta Capital |
Traceability
Source trail
Funding and investor claims retain their public-source links. This is a research snapshot, not a live cap table.